awmsg logo



pegfilgrastim (Neulasta®)


Reference No. 242

Publication date:
06/10/2008


Appraisal information

pegfilgrastim (Neulasta®) solution for injection


Company: Amgen Ltd
BNF category: Nutrition and blood
NMG meeting date: 16/07/2008
AWMSG meeting date: 13/08/2008
   
   
Submission Type: Full Submission
Status: Recommended with restrictions
Advice No: 1508
Ministerial ratification: 29/09/2008

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ministerial
Ratification

AWMSG advice

Pegfilgrastim (Neulasta®) is recommended as an option for restricted use within NHS Wales for the reduction in the duration of neutropenia and the incidence of febrile neutropenia in patients treated with cytotoxic chemotherapy for malignancy (with the exception of chronic myeloid leukaemia and myelodysplastic syndromes). Its use should be restricted to patients where the risk of febrile neutropenia is high and where the risk of neutropenia from chemotherapy is likely to be prolonged (more than six days) or for patients with special circumstances e.g. geographical access, needle phobia. Pegfilgrastim (Neulasta®) is not suitable for shared care within NHS Wales.
Final Appraisal Recommendation (FAR)
Download